Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation
Karen L. Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Vered Stearns(Johns Hopkins University), Carol Riley(Sidney Kimmel Comprehensive Cancer Center), Amanda L. Blackford(Johns Hopkins University), John H. Fetting(Johns Hopkins University), Raquel Nunes(Harvard University), Katie Papathakis(Sidney Kimmel Comprehensive Cancer Center), Antonio C. Wolff(Johns Hopkins University), Neha Verma(University of North Carolina at Chapel Hill), Claire Snyder(Johns Hopkins University), Jennifer Lehman(Johns Hopkins University), Kelly Westbrook(Duke Medical Center), Nelli Zafman(Sidney Kimmel Comprehensive Cancer Center), David K. Lim(Sidney Kimmel Comprehensive Cancer Center), Jennifer Y. Sheng(Johns Hopkins University), Kala Visvanathan(Johns Hopkins University), Deborah K. Armstrong(Johns Hopkins University), Robert S. Miller(American Society of Clinical Oncology), Daniela Jelovac(Johns Hopkins University), Roisín M. Connolly(Johns Hopkins University)
Cited by 28
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k